drugset / Trial / NCT02696967

A Study of CLR325 in Chronic Stable Heart Failure Patients.

NCT02696967 ↗

Phase 2 Completed 26 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.

Timeline

Start
2016-05-17
Primary completion
2019-01-14
Completion
2019-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject CLR325 Unknown — Intravenous

Indications